Locomotor activity is a measure of animal behavior which is employed in scientific research. Hyperlocomotion, also known as locomotor hyperactivity, hyperactivity, or increased locomotor activity, is an effect of certain drugs in animals in which locomotor activity (locomotion) is increased. It is induced by certain drugs like psychostimulants and NMDA receptor antagonists and is reversed by certain other drugs like antipsychotics and certain antidepressants. Stimulation of locomotor activity is thought to be mediated by increased signaling in the nucleus accumbens, a major brain area involved in behavioral activation and motivated behavior. Hypolocomotion, also known as locomotor hypoactivity, hypoactivity, and decreased locomotor activity, is an effect of certain drugs in animals in which locomotor activity is decreased. It is a characteristic effect of many sedative agents and general anesthetics. Antipsychotics, which are dopamine receptor antagonists, and many serotonergic agents, such as meta-chlorophenylpiperazine (mCPP), can also produce this effect, often as a side effect. Although locomotor activity is mainly an animal behavior test, it has also been evaluated in humans. People with attention deficit hyperactivity disorder (ADHD), in the manic phase of bipolar disorder, on acute amphetamine, and with schizophrenia show increased locomotor activity, while children with autism show decreased locomotor activity. Conversely, reduced locomotor activity is observed in bipolar individuals on mood stabilizers and may be a characteristic symptom of the inattentive type of ADHD (ADHD-PI) and sluggish cognitive tempo.
Drugs affecting locomotor activity
Dopaminergic agents
Dopamine releasing agents Hyperlocomotion is induced by dopamine releasing agents (DRAs) and psychostimulants like amphetamine and methamphetamine. These drugs likewise induce stereotypies.
Dopamine reuptake inhibitors The dopamine reuptake inhibitors (DRIs) amineptine, bupropion, and nomifensine increase spontaneous locomotor activity in animals. The DRI cocaine increases locomotor activity similarly to the preceding DRIs and to amphetamines. The atypical DRI modafinil does not produce hyperlocomotion in animals.
Dopamine receptor agonists Direct dopamine receptor agonists like apomorphine show biphasic effects, decreasing locomotor activity at low doses and increasing locomotor activity at high doses.
Dopamine receptor antagonists Drug-induced hyperlocomotion can be reversed by various drugs, such as antipsychotics acting as dopamine D2 receptor antagonists. Reversal of drug-induced hyperlocomotion has been used as an animal test of drug antipsychotic-like activity. Reversal of amphetamine- and NMDA receptor antagonist-induced stereotypies is also employed as a test of drug antipsychotic-like activity.
Adrenergic agents
… excerpt ends here. Continue reading the full article.


